An additional regulatory application is also under review in the european union, with a decision expected by the first half of 2026. Cemiplimab is the first immunotherapy approved for adjuvant treatment in cscc, offering a new option for patients at high risk of recurrence. See important safety & full prescribing information. The fda has approved libtayo for the adjuvant treatment of adult patients with cscc at high risk of recurrence after surgery and radiation. In a significant step forward for skin cancer management, the u.s Which cancers is libtayo currently approved to treat
What is the recommended dosage of libtayo?
OPEN
